With more than 100-million back in locked in China, why isn’t the U.S. media talking about recurrent risk? Sure, it’s great if someone has found a potential vaccine.
But even with a “silver bullet”: at the ready, there are logistical and ethical problems all over the place. Starting with track, adjuvants, preservatives, and more.
The problem is “we little people” won’t have much input to what goes on over on the medical or legal frontiers.
Where we do have incredible personal power is in planning out strategies should a “Round 2” happen in America, just as it is in China.
Before we jump into the deep end, however, a bit of headline sampling, the ChartPack on markets, and some coffee.
‘Round Two’ may seem like a boxing term, but around here? More like outside the box…
More for Subscribers ||| Not a Subscriber? SUBSCRIBE NOW! ||| Subscriber Help Center